Reta

Description

Reta

Overview: Reta is a synthetic multi-agonist peptide analogue. It has been designed to activate three key receptors — GLP-1, GIP, and the glucagon receptor (GCGR) — making it distinct from single or dual incretin mimetics. This triple-receptor activity has driven research into its effects on body weight, metabolic health, and glycemic control.

How It Works

• GLP-1 activity: Promotes insulin secretion, reduces glucagon when glucose is elevated, slows gastric emptying, and enhances satiety.
• GIP activity: Improves insulin sensitivity and supports glucose-dependent insulin release.
• Glucagon receptor activity: Increases energy expenditure and influences fat metabolism, adding a thermogenic component to weight regulation.

Research & Clinical Interest

• Weight Management: Early clinical studies reported dramatic weight reductions in participants with obesity, exceeding many other incretin-based therapies.
• Glucose Regulation: Reta improved glycemic control in type 2 diabetes trials by enhancing insulin sensitivity and reducing postprandial glucose spikes.
• Metabolic Health: Multi-pathway action may offer benefits for lipid metabolism and energy balance.

Pharmacology

Reta is engineered for extended half-life, supporting once-weekly injection schedules in clinical testing. By engaging three receptors simultaneously, it delivers a broader metabolic effect compared to single- or dual-agonist peptides.

Bottom Line

Reta is a next-generation multi-agonist peptide studied for its profound weight loss and metabolic benefits. Its triple action on GLP-1, GIP, and glucagon receptors makes it one of the most promising research compounds in the incretin analogue class.

Research Use Only: Reta is supplied strictly for laboratory and research purposes. It is not approved for human consumption, medical, or veterinary use.